Welcome
Support Centre
30 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
40kD pegylated interferon alpha 2a plus ribavirin compared to 40 kD pegylated interferon alpha 2a plus ribavirin and mycophenolate in the management of patients with refractory chronic HCV infection
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN52566041
Date ISRCTN assigned30/09/2004
Local reference number(s)N0060110647
Public title40kD pegylated interferon alpha 2a plus ribavirin compared to 40 kD pegylated interferon alpha 2a plus ribavirin and mycophenolate in the management of patients with refractory chronic HCV infection
Scientific title
AcronymN/A
Disease/condition/study domainInfections and Infestations: Hepatitis C
Study hypothesisIn treating chronic HCV patients who failed to respond to standard interferon X, is the combination of PEG interferon plus ribervirin plus mycophenolate better than PEG plus ribavirin?
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria60 patients in each arm - 15-25 from C&W.
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/04/2002
Anticipated end date01/04/2004
Status of trialCompleted
Target number of participants60
InterventionsRandomised, prospective trial.
Primary outcome measure(s)Sustained response 24-28 weeks post completion of therapy.
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingChelsea and Westminster Healthcare NHS Trust
Sponsor nameRecord Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
Sponsor detailsThe Department of Health, Richmond House, 79 Whitehall
London
United Kingdom
SW1A 2NL
Sponsor telephone+44 (0)20 7307 2622
Sponsor emaildhmail@doh.gsi.org.uk
Sponsor websitehttp://www.dh.gov.uk/Home/fs/en
Contact nameDr David Westaby
Contact detailsGastroenterology Dept
4th Floor, Management 3
Chelsea and Westminster Hospital
369 Fulham Road
London
United Kingdom
SW10 9NH
Contact telephone+44 (0) 20 8746 1076
Contact faxx8100
Contact emailkaren.hawkins@chelwest.nhs.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN52566041
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central